



Surbhi Sidana, MD

Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Medicine - Blood & Marrow Transplantation

CLINICAL OFFICE (PRIMARY)

- **Blood and Marrow Transplantation**

875 Blake Wilbur Dr Clinic C

MC 5820

Stanford, CA 94305

Tel (650) 498-6000 Fax (650) 725-3321

Bio

BIO

Dr. Surbhi Sidana is an Associate Professor of Medicine at Stanford University and specializes in the treatment of multiple myeloma and related disorders. She leads the Myeloma CAR-T/Immunotherapy program at Stanford.

Dr Sidana grew up in Delhi, India. She completed her Internal Medicine Residency at Cleveland Clinic in Cleveland, Ohio, followed by Hematology/Oncology fellowship at Mayo Clinic in Rochester, MN. Following this, she completed an Advanced Hematology Fellowship in Myeloma, Amyloidosis and Related Disorders at Mayo Clinic in Rochester, MN before joining Stanford University as a faculty member in 2019, where she has led the development of the myeloma CAR-T and bispecific antibody program.

Dr Sidana has an active, broad research portfolio that includes clinical trials of novel therapies in myeloma and related disorders, translational research, epidemiologic and patient reported outcome studies. She has a special focus on research with immunotherapies such as CAR-T cell therapy and bispecific antibodies. She has published over 100 research manuscripts. Dr Sidana is the Leader of the Myeloma Disease Focused Group and the Associate Director for Clinical Research in the BMT and Cell Therapy Division at Stanford University. She also co-leads a multi-institutional collaboration on real world outcomes with immunotherapies in myeloma.

Dr Sidana is actively involved in and holds leadership positions in national and international professional societies. She is the Chair of the American Society of Hematology Committee on Communications, and Co-Chairs the Quality-of-Life Committee of the International Myeloma Working Group. She is a member of the SWOG Myeloma Committee and BMT CTN Myeloma Intergroup, where she works with colleagues across the nation to develop innovative and practice changing trials focused on multiple myeloma .

CLINICAL FOCUS

- Multiple Myeloma
- Amyloidosis

- POEMS Syndrome
- Waldenstrom's Macroglobulinemia
- Cryoglobulinemia
- CAR-T Cell Therapy
- Hematopoietic Stem Cell Transplantation
- Hematology

ACADEMIC APPOINTMENTS

- Associate Professor - University Medical Line, Medicine - Blood & Marrow Transplantation
- Member, Bio-X
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Clinical Research Group Co-Leader for BMT/Cell Therapy, Stanford Cancer Institute, (2024- present)
- Associate Director for Clinical Research, BMT/Cell Therapy, Stanford University, (2024- present)
- Leader, Myeloma Disease Focused Group, BMT/Cell Therapy, Stanford University, (2021- present)

HONORS AND AWARDS

- Exemplary Abstract Award, International Myeloma Society (2023)
- Merit Award, American Society of Clinical Oncology/Conquer Cancer Foundation (2019)
- Hematology/Oncology Outstanding Fellow, Mayo Clinic, Rochester, MN (2018)
- Junior Researcher Travel Award, Amyloidosis Foundation (2018)
- Outstanding Research Fellow, Department of Medicine, Mayo Clinic, Rochester, MN (2018)
- Research Grant for Early Career Investigators, Amyloidosis Foundation (2018)
- Young Investigator Award, 10th International Workshop on Waldenstrom's Macroglobulinemia (2018)
- Clinical Research Training Institute, American Society of Hematology (2017)
- Merit Award, American Society of Clinical Oncology/Conquer Cancer Foundation (2017)
- Outstanding Fellow Award, Minnesota Society of Clinical Oncology (2017)
- Research Grant (Co-Principal Investigator), International Waldenstrom's Macroglobulinemia Foundation (2017)
- Young Investigator Award, American Society of Clinical Oncology/Conquer Cancer Foundation (2017)
- Abstract Achievement Award, American Society of Hematology (2016)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Chair, Committee on Communications, American Society of Hematology (2025 - present)
- Co-Chair, Quality of Life Committee, International Myeloma Working Group (2023 - present)
- Co-Chair, Committee on trainees and junior faculty, American Society of Transplantation and Cellular Therapy (2019 - 2023)

PROFESSIONAL EDUCATION

- Board Certification: Medical Oncology, American Board of Internal Medicine (2018)
- Board Certification: Hematology, American Board of Internal Medicine (2018)
- Residency: Cleveland Clinic Foundation (2015) OH
- Fellowship, Mayo Clinic, Rochester, MN , Myeloma, Amyloidosis and Related Disorders (Advanced Hematology)

- Fellowship, Mayo Clinic, Rochester, MN , Hematology and Oncology
- Residency, Cleveland Clinic, OH , Internal Medicine
- Medical Education, Maulana Azad Medical College, University of Delhi, India

Research & Scholarship

CLINICAL TRIALS

- Expanded Access Program for Ciltacabtagene autoleucl Out-of-Specification (OOS) in Multiple Myeloma, Recruiting
- Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel, Recruiting
- Expanded Access Protocol (EAP) in Idecabtagene Vicleucl that is Nonconforming for CommercialRelease, Recruiting
- Long-Term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucl, Recruiting
- Long-term Follow-up Study of Subjects w/ Malignancies Treated With CRISPR CAR Cellular Therapies, Recruiting
- Phase I BMS-986453 Dual Targeting BCMAxGPCR5D CAR-T Cells in Relapsed&/or Refractory MultipleMyeloma, Recruiting
- Phase II Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma, Recruiting
- Phase I ALLO-715 &ALLO-647 Eval Anti-BCMA Allogeneic CAR T Cell Treatment +/- Nirogacestat in R/R MM, Not Recruiting
- Phase I CC-98633 BCMA Targeted NEX-T CAR T Cells, in Relapsed and/or Refractory Multiple Myeloma, Not Recruiting
- Phase I/II Teclistamab Humanized BCMAxCD3 Bispecific Antibody in Relapsed/Refractory MultipleMyeloma, Not Recruiting
- Phase II DurcabtageneAutoleucl BCMA-DirectedCAR-TCells in Adult Relapsed&Refractory MultipleMyeloma, Not Recruiting
- Phase II JNJ-68284528 (Ciltacabtagene Autoleucl) OoS for Commercial Release in Multiple Myeloma, Not Recruiting
- Phase II MGTA-145 +/- Plerixafor in the Mobilization of HSCs for Autologous Transplantation in MM, Not Recruiting
- Phase II T Cell Therapy in MM w/Sub-Optimal Response After Autologous HCT & Maintenance Lenalidomide, Not Recruiting
- Phase III Comparing DVRd +Ciltacabtagene Autoleucl vs DVRd +ASCT in Newly Diagnosed MultipleMyeloma, Not Recruiting
- Phase III JNJ-68284528 CAR-T Tx vs PVd or DPd in Relapsed & Lenalidomide-Refractory Multiple Myeloma, Not Recruiting
- Phase III Teclistamab Daratumumab Pomalidomide Dexamethasone Bortezomib in RR Multiple Myeloma, Not Recruiting
- Talquetamab Expanded Access Treatment Protocol in Relapsed or Refractory Multiple Myeloma, Not Recruiting
- Open-Label Phase Ib Study Evaluating the Safety & Efficacy of ABBV-383 in AL Amyloidosis, Not Specified
- PhaseI/II ALLO-647&ALLO-605 Anti-BCMA Allogeneic CAR TCell Tx in Relapsed/Refractory MultipleMyeloma, Not Specified

Publications

PUBLICATIONS

- **Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.** *Blood cancer journal*
Dima, D., Vazquez-Martinez, M. A., Davis, J. A., Goel, U., Afrough, A., Sannareddy, A., Pasvolsky, O., Razzo, B., Banerjee, R., Khouri, J., Grajales-Cruz, A., Lieberman-Cribbin, A., Rana, et al
2025; 15 (1): 111
- **Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies.** *The Lancet. Haematology*
Bröckelmann, P. J., Scheffer Cliff, E. R., Iacoboni, G., Simon, F., Horowitz, M. M., Keating, A., Mateos, M. V., Mohty, M., Sidana, S., Song, Y., Wingard, J. R., Thanarajasingam, G.
2025; 12 (6): e470-e481
- **Fatal Recurrence of IEC-HS Following Autologous Stem Cell Boost in Patients Receiving BCMA CAR-T Cell Therapy.** *Blood advances*
Ananth, S., Torres, N. E., Sahaf, B., Mikkilineni, L., Fernandez-Pol, S., Salmi, D., Negrin, R. S., Shiraz, P., Smith, M., Bharadwaj, S., Weng, W. K., Kennedy, V. E., Dahiya, et al
2025

- **Comparative Efficacy of Ciltacabtagene Autoleucl Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison.** *Advances in therapy*
Puig, N., Diels, J., van Sanden, S., Mendes, J., Burnett, H., Cichewicz, A., Lee, S., Hernando, T., Schechter, J. M., Lendvai, N., Patel, N., Sanchez-Pina, J. M., Rocchi, et al
2025
- **Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.** *Blood cancer journal*
Pasvolsky, O., Dima, D., Feng, L., Dong, W., Richards, T., Davis, J. A., Afrough, A., Vazquez-Martinez, M., Sannareddy, A., Goel, U., Banerjee, R., Khouri, J., Cervoni, et al
2025; 15 (1): 92
- **Teclistamab for Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma and Renal Impairment.** *Blood advances*
Dima, D., Afrough, A., Goel, U., Grajales-Cruz, A., Khouri, J., Julian, K., Pasvolsky, O., Banerjee, R., Razzo, B., Ferreri, C. J., Vazquez Martinez, M. A., Davis, J. A., Sannareddy, et al
2025
- **Standard-of-Care Idecabtagene Vicleucl for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.** *Blood*
Sidana, S., Ahmed, N., Akhtar, O. S., Brazauskas, R., Oloyede, T., Bye, M., Hansen, D. K., Ferreri, C. J., Freeman, C. L., Afrough, A., Anderson, L. D., Dhakal, B., Dhanda, et al
2025
- **Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma.** *Blood advances*
Banerjee, R., Richards, A., Midha, S., Afrough, A., Anwer, F., Atanackovic, D., Atrash, S., Bachanova, V., Beitinjaneh, A. M., Ouchveridze, E., Castaneda Puglianini, O., Chhabra, S., Cicero, et al
2025
- **Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma.** *Nature communications*
Hosoya, H., Carleton, M., Tanaka, K., Sworder, B., Syal, S., Sahaf, B., Maltos, A. M., Silva, O., Stehr, H., Hovanky, V., Duran, G., Zhang, T., Liedtke, et al
2025; 16 (1): 1824
- **Comparison of Standard-of-Care Idecabtagene Vicleucl and Ciltacabtagene Autoleucl in Relapsed/Refractory Multiple Myeloma.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Hansen, D. K., Peres, L. C., Dima, D., Richards, A., Shune, L., Afrough, A., Midha, S., Dhakal, B., Kocoglu, M. H., Atrash, S., Ferreri, C., Castaneda, O., Davis, et al
2025: JCO2401730
- **Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease.** *Blood*
Meyer, E., Pavlova, A., Villar-Prados, A., Bader, C. S., Xie, B., Muffly, L., Kim, P., Sutherland, K. C., Bharadwaj, S., Dahiya, S., Frank, M. J., Arai, S., Johnston, et al
2025
- **Outcomes of Older Adults and Frail Patients Receiving Idecabtagene Vicleucl: A CIBMTR Study.** *Blood advances*
Akhtar, O. S., Oloyede, T., Brazauskas, R., Afrough, A., Hashmi, H., Sidana, S., Ahmed, N., Bye, M., Hansen, D. K., Ferreri, C. J., Dhakal, B., Dhanda, D. S., Harrison, et al
2024
- **Indolent CD8+CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucl Therapy for Relapsed/Refractory Multiple Myeloma**
Hosoya, H., Fernandez-Pol, S., Gubatan, J., Ehlinger, Z., Lohman, C., Torres, A., Najidh, S., Kwang, A., Duran, G., Wright, C., Kennedy, V. E., Bharadwaj, S., Smith, et al
ELSEVIER.2024: 4846-4847
- **Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucl or Ciltacabtagene Autoleucl**
Peres, L. C., Richards, A., Sidana, S., Oswald, L. B., Dima, D., Afrough, A., Shune, L. O., Midha, S., Castaneda, O., Ferreri, C., Davis, J. A., Pasvolsky, O., Dillard, et al
ELSEVIER.2024
- **Anti-BCMA CAR T-Cell Expansion and Its Association with Response and Toxicity in Multiple Myeloma**

- Hosoya, H., Jensen, A., Hovanky, V., Homsy, S., Cancilla, J. E., Patil, S., Kennedy, V. E., Bharadwaj, S., Smith, M., Shiraz, P., Frank, M. J., Dahiya, S., Arai, et al
ELSEVIER.2024: 2006-2007
- **Comparative Effectiveness of Ciltacabtagene Autoleucl from the Cartitude-4 Trial Vs Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma- an Updated Overall Survival Analysis**
Touzeau, C., Lipe, B., Khan, A., Dhakal, B., Nair, S., He, J., Mendes, J., Lee, S., Lonardi, C., Slaughter, A., Lendvai, N., Schechter, J. M., Chen, et al
ELSEVIER.2024: 7090-7091
 - **Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the US Multiple Myeloma Immunotherapy Consortium**
Dima, D., Vazquez-Martinez, M. A., Davis, J. A., Goel, U., Afrough, A., Sannareddy, A., Pasvolsky, O., Razzo, B., Banerjee, R., Khouri, J., Grajales-Cruz, A., Lieberman-Cribbin, A., Rana, et al
ELSEVIER.2024: 897-899
 - **Comparative Efficacy of Ciltacabtagene Autoleucl Versus Isatuximab, Carfilzomib and Dexamethasone in the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma with 1-3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison**
Mina, R., Corradini, P., Cavo, M., San-Miguel, J. F., Shune, L. O., Khan, A., Sidana, S., Leleu, X., Manier, S., Lipe, B., Weisel, K. C., van Sanden, S., Diels, et al
ELSEVIER.2024: 7088-7090
 - **Global Manufacturing Experience with Idecabtagene Vicleucl in Patients with Relapsed and Refractory Multiple Myeloma**
Sidana, S., Scheid, C., Mueller, P. J., Schuberth, P., Modi, H., Krenkel, P., Piau, R., Zhong, X., Rodriguez-Otero, P.
ELSEVIER.2024: 3476-3477
 - **Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)**
Dhakal, B., Akhtar, O. S., Cowan, A. J., Richard, S., Friend, R., Rees, M. J., Costello, P., Martinez, M., Pasvolsky, O., Wagner, C. B., Jensen, A., Davis, J. A., Reshef, et al
ELSEVIER.2024: 931-933
 - **CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma**
Kramer, A., Srinagesh, H., Su, Y., Hamilton, M. P., Levine, K., Migliore, E., Denoble, K., Brown, A. K., Cunanan, K., Agarwal, N., Lohman, C., Mavroukakis, S., Bharadwaj, et al
ELSEVIER.2024: 2064-2066
 - **Point-of-Care Bispectral Electroencephalogram (BSEEG) As a New Tool in Detecting Immune Effector Cell Associated Neurotoxicity (ICANS) in Patients Treated with Chimeric Antigen Receptor T-Cell (CAR-T)**
Homsy, S., Seki, T., Nguyen, H., Shimura, A., Gorantla, N., Phuong, N., Ghalehsari, N., Velayati, A., Jeyakumar, N., Hamilton, M. P., Kennedy, V. E., Mikkilineni, L., Bharadwaj, et al
ELSEVIER.2024: 7134-7135
 - **Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL**
Muffy, L., Ananth, S., Danley, L., Wagner, C., Kordek, D., Denoble, K., Fraser, A., Egeler, E., Molina, A., Ehlinger, Z., Desai, M., Daghigh, H., Tunuguntla, et al
ELSEVIER.2024: 680
 - **Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged > 80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)**
Lee, D., Bharadwaj, S., Rana, M. S., Jensen, A., Wang, W., Ghalehsari, N., Sahaf, B., Mallampet, J., Elkordy, S., Latchford, T., Arai, S., Johnston, L., Hosoya, et al
ELSEVIER.2024: 386-387
 - **Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium**
Banerjee, R., Richards, A., Khouri, J., Janakiram, M., Cicero, K. I., Dima, D., Kocoglu, M. H., Shune, L. O., Ouchveridze, E., Jain, T., Afrough, A., Zanwar, S., Ferreri, et al
ELSEVIER.2024: 3765-3768
 - **Comparative Safety and Efficacy of Ciltacabtagene Autoleucl and Idecabtagene Vicleucl CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma**

- Hansen, D. K., Peres, L. C., Dima, D., Richards, A., Shune, L. O., Afrough, A., Midha, S., Dhakal, B., Kocoglu, M. H., Atrash, S., Ferreri, C., Castaneda, O., Davis, et al
ELSEVIER.2024: 937-939
- **Pooled Efficacy and Safety of Teclistamab in 217 Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from 3 Registrational Clinical Studies**
Martin, T. G., Mateos, M., van de Donk, N. J., Cai, Z., Fu, W., Garfall, A. L., Iida, S., Kuroda, Y., Niu, T., Nooka, A. K., Sidana, S., Chastain, K., Doyle, et al
ELSEVIER.2024: 3331-3333
 - **Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the US Multiple Myeloma Immunotherapy Consortium**
Pasvolsky, O., Dima, D., Feng, L., Dong, W., Richards, T., Davis, J. A., Afrough, A., Vazquez-Martinez, M. A., Sannareddy, A., Goel, U., Banerjee, R., Khouri, J., Curet, et al
ELSEVIER.2024: 934-937
 - **A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis**
Hagen, P., Sidana, S., Parker, T. L., Walker, B. A., Santhorawala, V., Zonder, J. A., Kourelis, T., D'Souza, A., Landau, H., Rosenthal, A., Hoering, A., Ailawadhi, S., Orlowski, et al
ELSEVIER.2024: 33091-33092
 - **Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab**
Pasvolsky, O., Afrough, A., Feng, L., Dong, W., Richards, T., Davis, J. A., Dima, D., Grajales-Cruz, A., Vazquez-Martinez, M. A., Sannareddy, A., Goel, U., Banerjee, R., Gaballa, et al
ELSEVIER.2024: 3337-3339
 - **CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up**
Kramer, A., Baird, J. H., Srinagesh, H., Egeler, E., Levine, K., Brown, A. K., Mavroukakis, S., Cunanan, K., Su, Y., Agarwal, N., Hamilton, M. P., Bharadwaj, S., Arai, et al
ELSEVIER.2024: 70-71
 - **Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms**
Hamilton, M., Phillips, N., Lee, D., Ehlinger, Z., Kramer, A., Srinagesh, H., Good, Z., Kang, X., Olsen, M., Liu, C., Tian, F., Sworder, B. J., Hosoya, et al
ELSEVIER.2024: 96-97
 - **Treatment Patterns and Outcomes in Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma: Findings from the Flatiron Database**
Sidana, S., Thirumalai, D., Itani, T., Baro, E., Giordana, M., Granados, E., Hasegawa, K., Rosado, M. B., Chan, R. J., Kostic, A., Banerjee, K., Patel, K. K., Hansen, et al
ELSEVIER.2024: 6962-6963
 - **Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma. *Blood cancer journal***
Fortuna, G. G., Banerjee, R., Savid-Frontera, C., Song, J., Morán-Segura, C. M., Nguyen, J. V., Lekakis, L., Fernandez-Pol, S., Samraj, A. N., Naresh, K. N., Vazquez-Martinez, M., Baz, R. C., Spiegel, et al
2024; 14 (1): 180
 - **Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma. *Blood cancer journal***
Sidana, S., Bankova, A. K., Hosoya, H., Kumar, S. K., Holmes, T. H., Tamaresis, J., Le, A., Muffly, L. S., Maysel-Auslender, S., Johnston, L., Arai, S., Lowsky, R., Meyer, et al
2024; 14 (1): 173
 - **Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucl for Relapsed/Refractory Multiple Myeloma. *Blood***
Sidana, S., Patel, K. K., Peres, L. C., Bansal, R., Kocoglu, M. H., Shune, L., Atrash, S., Smith, K., Midha, S., Ferreri, C. J., Dhakal, B., Dima, D., Costello, et al
2024

- **Linvoseltamab Still Efficacious Despite CRL in Multiple Myeloma** *ONCOLOGY-NEW YORK*
Sidana, S.
2024; 38 (10)
- **PHASE 1 TRIAL RESULTS FOR PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES TREATED WITH ORCA-T CELL THERAPY WITH REDUCED INTENSITY CONDITIONING AND SINGLE AGENT TACROLIMUS**
Villar-Prados, A., Sutherland, K., Negrin, R., Arai, S., Frank, M., Johnston, L., Lowsky, R., Miklos, D., Muffly, L., Dahiya, S., Rezvani, A., Sidana, S., Shiraz, et al
SPRINGER NATURE.2024: 287-288
- **T-cell redirecting bispecific antibodies in multiple myeloma: optimal dosing-schedule and duration of treatment.** *Blood cancer discovery*
van de Donk, N. W., Rasche, L., Sidana, S., Zweegman, S., Garfall, A. L.
2024
- **Real-World Experience with Teclistamab for Relapsed/ Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium**
Razzo, B., Grajales-Cruz, A., Atrash, S., Ferreri, C., Goyal, A., Pasvolosky, O., Banerjee, R., Julian, K., Forsberg, P., Herr, M., Lin, Y., Susanibar-Adaniya, S., Khouri, et al
CIG MEDIA GROUP, LP.2024: S82-S83
- **Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)**
Garfall, A. L., Nooka, A. K., van de Donk, N. J., Moreau, P., Bhutani, M., Oriol, A., Martin, T. G., Rosinol, L., Mateos, M., Bahlis, N., Popat, R., Besemer, B., Martinez-Lopez, et al
CIG MEDIA GROUP, LP.2024: S548
- **Absolute Lymphocyte Count at Day 30 (Not Earlier) and Early CRS Predict Delayed Responses to Teclistamab: Results From the US Myeloma Immunotherapy Consortium**
Banerjee, R., Kaur, G., Razzo, B., Portuguese, A., Sidana, S., Richards, T., Grajales-Cruz, A., Richard, S., Shune, L., Khouri, J., Dima, D., Lee, H., Patel, et al
CIG MEDIA GROUP, LP.2024: S43-S44
- **Ciltacabtagene Autoleucl vs Standard of Care in Patients With Functionally High-Risk Multiple Myeloma: CARTITUDE-4 Subgroup Analysis**
Sidana, S., Weisel, K., Costa, L., van de Donk, N., Cohen, Y., Purtil, D., Touzeau, C., de Larrea, C., Martinez-Lopez, J., Lendvai, N., Slaughter, A., Lonardi, C., Zhao, et al
CIG MEDIA GROUP, LP.2024: S89
- **Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucl (Cilta-cel) for Relapsed/Refractory Multiple Myeloma (RRMM): Real World Experience With Updated Follow-up**
Sidana, S., Patel, K., Peres, L., Bansal, R., Kocoglu, M., Atrash, S., Dima, D., Smith, K., Ferreri, C., Midha, S., Dhakal, B., Herr, M., Nadeem, et al
CIG MEDIA GROUP, LP.2024: S7-S8
- **A Comparison of Standard of Care Idecabtagene Vicleucl and Ciltacabtagene Autoleucl CAR T-cell Therapy in Relapsed or Refractory Multiple Myeloma**
Hansen, D., Peres, L., Dima, D., Richards, A., Shune, L., Afrough, A., Midha, S., Dhakal, B., Kocoglu, M. H., Ferreri, C., Davis, J., Herr, M., Forsberg, et al
CIG MEDIA GROUP, LP.2024: S5
- **Comparative Efficacy of Cilta- Cel vs Approved Comparator Treatments for Patients With Relapsed/Refractory Multiple Myeloma With 1-3 Prior Lines of Therapy: A Network Meta-Analysis**
Mina, R., Khan, A., McClune, B., Bar, N., Caers, J., Larsen, J., Mendes, J., Lee, S., Benachour, N., Chen, D., Zhao, M., Lonardi, C., Slaughter, et al
CIG MEDIA GROUP, LP.2024: S74
- **Overall Survival (OS) With Ciltacabtagene Autoleucl (Cilta-cel) Versus Standard of Care (SoC) in Lenalidomide (Len)-Refractory Multiple Myeloma (MM): Phase 3 CARTITUDE-4 Study Update**
Mateos, M., San-Miguel, J., Dhakal, B., Touzeau, C., Leleu, X., van de Donk, N. J., Sidana, S., Oriol, A., Cohen, Y. C., Harrison, S. J., Einsele, H., Corradini, P., Chen, et al
CIG MEDIA GROUP, LP.2024: S290
- **Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma**
Popat, R., Nooka, A., van de donk, N., Moreau, P., Bhutani, M., Oriol, A., Martin, T., Rosinol, L., Mateos Manteca, M., Bahlis, N. J., Garfall, A., Besemer, B., Martinez-Lopez, et al

CIG MEDIA GROUP, LP.2024: S80

- **Systematic Literature Review and Meta-Analysis of Clinical Trials of Fourth Line or Higher Treatment for Relapsed/Refractory Multiple Myeloma Patients**
Patel, K., Sidana, S., Hasegawa, K., Itani, T., Giordana, M., Jackson, C., Donelson, S., Chan, R., Kostic, A., Limbrick-Oldfield, E., Zoratti, M., Mateos Manteca, M., Hansen, et al
CIG MEDIA GROUP, LP.2024: S77-S78
- **Ocular Complications Are Common in Patients With Multiple Myeloma Receiving Dexamethasone: Results of a Cross-Sectional Patient Survey**
Banerjee, R., Barnes, M., Martinez, J., Perez, P., Hydren, J., Ahlstrom, J., Cicero, K., Kaur, G., Taravati, P., Cowan, A.
CIG MEDIA GROUP, LP.2024: S101-S102
- **Systematic Literature Review and Meta-Analysis of Clinical Trials of Fourth Line or Higher Treatment for Relapsed/Refractory Multiple Myeloma Patients**
Patel, K., Sidana, S., Hasegawa, K., Itani, T., Giordana, M., Jackson, C., Donelson, S., Chan, R., Kostic, A., Limbrick-Oldfield, E., Zoratti, M., Mateos Manteca, M., Hansen, et al
CIG MEDIA GROUP, LP.2024: S77-S78
- **Ocular Complications Are Common in Patients With Multiple Myeloma Receiving Dexamethasone: Results of a Cross-Sectional Patient Survey**
Banerjee, R., Barnes, M., Martinez, J., Perez, P., Hydren, J., Ahlstrom, J., Cicero, K., Kaur, G., Taravati, P., Cowan, A.
CIG MEDIA GROUP, LP.2024: S101-S102
- **Clinical Outcomes After Idecabtagene Vicleucef in Older Multiple Myeloma Patients: A Multicenter Real-world Experience.** *Blood advances*
Kalariya, N., Hildebrandt, M. A., Hansen, D. K., Sidana, S., Khouri, J., Ferreri, C. J., Doyle, W. N., Castaneda Puglianini, O. A., Freeman, C. L., Hovanky, V., Hosoya, H., Shune, L., Patel, et al
2024
- **CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.** *Lancet (London, England)*
Frank, M. J., Baird, J. H., Kramer, A. M., Srinagesh, H. K., Patel, S., Brown, A. K., Oak, J. S., Younes, S. F., Natkunam, Y., Hamilton, M. P., Su, Y. J., Agarwal, N., Chinnasamy, et al
2024
- **A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia.** *Blood*
Srinagesh, H. K., Jackson, C., Shiraz, P., Jeyakumar, N., Hamilton, M. P., Egeler, E., Mavroukakis, S., Kuo, A., Cancilla, J., Sahaf, B., Agarwal, N., Kanegai, A. M., Kramer, et al
2024
- **Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucef in patients with refractory or relapsed large B-cell lymphoma.** *Journal for immunotherapy of cancer*
Bharadwaj, S., Lau, E., Hamilton, M. P., Goyal, A., Srinagesh, H., Jensen, A., Lee, D., Mallampet, J., Elkordy, S., Syal, S., Patil, S., Latchford, T., Sahaf, et al
2024; 12 (7)
- **Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucef.** *Journal of hematology & oncology*
Zanwar, S., Sidana, S., Shune, L., Puglianini, O. C., Pasvolsky, O., Gonzalez, R., Dima, D., Afrough, A., Kaur, G., Davis, J. A., Herr, M., Hashmi, H., Forsberg, et al
2024; 17 (1): 42
- **Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucef: The U.S. Myeloma Immunotherapy Consortium Real World Experience.** *Transplantation and cellular therapy*
Khouri, J., Dima, D., Li, H., Hansen, D., Sidana, S., Shune, L., Anwer, F., Sborov, D., Wagner, C., Kocoglu, M. H., Atrash, S., Voorhees, P., Peres, et al
2024
- **Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma**
Garfall, A. L., Nooka, A. K., van de Donk, N. J., Moreau, P., Bhutani, M., Oriol, A., Martin, T. G., Rosinol, L., Mateos, M., Bahlis, N. J., Popat, R., Besemer, B., Martinez-Lopez, et al
LIPPINCOTT WILLIAMS & WILKINS.2024

- **Ciltacabtagene autoleucl vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis.** Costa, L. J., Weisel, K. C., van de Donk, N. J., Sidana, S., Cohen, Y. C., Purtill, D., Touzeau, C., de Larrea, C., Martinez-Lopez, J., Lendvai, N., Slaughter, A., Lonardi, C., Zhao, et al
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee.** *The Lancet. Oncology*
Lin, Y., Qiu, L., Usmani, S., Joo, C. W., Costa, L., Derman, B., Du, J., Einsele, H., Fernandez de Larrea, C., Hajek, R., Ho, P. J., Kastiris, E., Martinez-Lopez, et al
2024
- **Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium.** *Blood cancer journal*
Afrough, A., Hashmi, H., Hansen, D. K., Sidana, S., Ahn, C., Peres, L. C., Dima, D., Freeman, C. L., Puglianini, O. C., Kocoglu, M. H., Atrash, S., Voorhees, P. M., Shune, et al
2024; 14 (1): 63
- **CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.** *Blood advances*
Hamilton, M. P., Craig, E., Gentile Sanchez, C., Mina, A., Tamaresis, J., Kirmani, N., Ehlinger, Z., Syal, S., Good, Z., Sworder, B., Schroers-Martin, J., Lu, Y., Muffly, et al
2024
- **CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.** *Leukemia*
Schultz, L. M., Jeyakumar, N., Kramer, A. M., Sahaf, B., Srinagesh, H., Shiraz, P., Agarwal, N., Hamilton, M., Erickson, C., Jacobs, A., Moon, J., Baggott, C., Arai, et al
2024
- **INCIDENCE AND MANAGEMENT OF CRANIAL NERVE IMPAIRMENTS IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH CILTACABTAGENE AUTOLEUCEL IN CARTITUDE STUDIES**
Bennett, L., Kruyswijk, S., Sidana, S., Lee, E., Florendo, E., van de Donk, N.
ONCOLOGY NURSING SOC.2024
- **INCIDENCE AND MANAGEMENT OF CRANIAL NERVE IMPAIRMENTS IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH CILTACABTAGENE AUTOLEUCEL IN CARTITUDE STUDIES**
Bennett, L., Kruyswijk, S., Sidana, S., Lee, E., Florendo, E., van de Donk, N.
ONCOLOGY NURSING SOC.2024
- **Single Center Randomized Trial of T-reg graft alone versus T-reg graft Plus Tacrolimus for the Prevention of Acute GVHD.** *Blood advances*
Bader, C. S., Pavlova, A., Lowsky, R., Muffly, L., Shiraz, P., Arai, S., Johnston, L. J., Rezvani, A. R., Weng, W. K., Miklos, D. B., Frank, M. J., Tamaresis, J. S., Agrawal, et al
2023
- **Managing side effects: guidance for use of immunotherapies in multiple myeloma.** *Hematology. American Society of Hematology. Education Program*
Liang, E. C., Sidana, S.
2023; 2023 (1): 348-356
- **Integrating Immune Therapies for the Treatment of Multiple Myeloma.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Mikkilineni, L., Sidana, S.
2023; 21 (12): 1303-1311
- **CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias**
Hamilton, M. P., Sworder, B. J., Alig, S. K., Good, Z., Boegeholz, J., Schroers-Martin, J., Tamaresis, J., Esfahani, M., Lu, Y., Olsen, M., Liu, C., Ehlinger, Z., Desai, et al
AMER SOC HEMATOLOGY.2023
- **Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma**
Midha, S., Gurumurthi, A., Costello, P., Redd, R. A., Freeman, C. L., Castaneda, O., Gonzalez, R., Ionescu, F., Gaballa, M., Kalariya, N., Khouri, J., Dima, D., Kocoglu, et al

AMER SOC HEMATOLOGY.2023

- **Fludarabine Lymphodepletion Exposure Is Associated with Idecabtagene Vicleucel Toxicity in Relapsed and Refractory Multiple Myeloma Patients: Real-World Experience from the US Myeloma Immunotherapy Consortium**
Wagner, C. B., Sweiss, K., Anto, E., Gonzalez, R., Puglianini, O., Freeman, C. L., Ionescu, F., Patel, K. K., Ferreri, C., Gaballa, M., Shune, L., McGuirk, J. P., Sidana, et al
AMER SOC HEMATOLOGY.2023
- **Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma**
Sidana, S., Ahmed, N., Akhtar, O. S., Heim, M., Brazauskas, R., Hansen, D. K., Ferreri, C., Freeman, C. L., Afrough, A., Anderson, L. D., Dhakal, B., Dhand, D., Gowda, et al
AMER SOC HEMATOLOGY.2023
- **Clinical Experience with Cranial Nerve Impairment in the CARTITUDE-1, CARTITUDE-2 Cohorts A, B, and C, and Cartitude-4 Studies of Ciltacabtagene Autoleucel (Cilta-cel)**
Van De Donk, N. J., Sidana, S., Schechter, J. M., Jackson, C., Lendvai, N., De Braganca, K. C., Slaughter, A., Lonardi, C., Vlummens, P., Varsos, H., Corsale, C., Madduri, D., Jadidi, et al
AMER SOC HEMATOLOGY.2023
- **Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus**
Villar-Prados, A., Meyer, E. H., Sutherland, K., Negrin, R. S., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., Miklos, D. B., Muffly, L. S., Dahiya, S., Rezvani, A. R., Sidana, et al
AMER SOC HEMATOLOGY.2023
- **CAR T-Cell therapy for Myeloma: Where are we now and what is needed to move CAR T-cells forward to earlier lines of therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. *Transplantation and cellular therapy***
Anderson, L. D., Dhakal, B., Jain, T., Oluwole, O. O., Shah, G. L., Sidana, S., Perales, M. A., Pasquini, M. C.
2023
- **Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: U.S. Myeloma Immunotherapy Consortium real world experience. *Haematologica***
Hashmi, H., Hansen, D. K., Peres, L. C., Puglianini, O. C., Freeman, C., De Avila, G., Sidana, S., Shune, L., Sborov, D. W., Davis, J., Wagner, C., Kocoglu, M. H., Atrash, et al
2023
- **Racial and ethnic differences in clinical outcomes among multiple myeloma patients treated with CAR T-cell therapy. *Blood advances***
Peres, L. C., Oswald, L. B., Dillard, C. M., De Avila, G., Nishihori, T., Blue, B. J., Freeman, C. L., Locke, F. L., Alsina, M., Castaneda Puglianini, O. A., Shune, L., Sborov, D. W., Wagner, et al
2023
- **Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma. *Blood cancer journal***
Sidana, S., Hosoya, H., Jensen, A., Liu, L., Goyal, A., Hovanky, V., Sahaf, B., Bharadwaj, S., Latchford, T., Arai, S., Leahy, S., Mei, M., Budde, et al
2023; 13 (1): 158
- **First phase 3 results from CARTITUDE-4: cilta-cel versus standard of care (Pvd or DPd) in lenalidomide-refractory multiple myeloma**
Dhakal, B., Yong, K., Harrison, S., Mateos, M., Moreau, P., van de Donk, N. W., Sidana, S., Popat, R., Lendvai, N., Lonardi, C., Slaughter, A., Schechter, J. M., Li, et al
KARGER.2023: 81-82
- **Long-term follow-up from MajesTEC-1 of Teclistamab, a B-cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in patients with Relapsed/Refractory Multiple Myeloma (RRMM)**
Donk, V. W., Moreau, P., Garfall, A. L., Bhutani, M., Oriol, A., Nooka, A. K., Martin, T. G., Rosinol, L., Mateos, M., Bahlis, N., Popat, R., Besemer, B., Lopez, et al
KARGER.2023: 124
- **Long-Term Follow-Up From the MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)**
van de Donk, N. J., Moreau, P., Garfall, A. L., Bhutani, M., Oriol, A., Nooka, A. K., Martin, T. G., Rosinol, L., Mateos, M., Bahlis, N., Popat, R., Besemer, B., Martinez Lopez, et al
WILEY.2023: S25-S26

- **Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment.** *Haematologica*
Sidana, S., Peres, L. C., Hashmi, H., Hosoya, H., Ferreri, C., Khouri, J., Dima, D., Atrash, S., Voorhees, P., Simmons, G., Sborov, D. W., Kalariya, N., Hovanky, et al
2023
- **Safety and efficacy of standard of care ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM): real world experience**
Sidana, S., Patel, K., Peres, L., Bansal, R., Kocoglu, M., Shune, L., Atrash, S., Smith, K., Ferreri, C., Dhakal, B., Chhabra, S., Parrondo, R., Costello, et al
CIG MEDIA GROUP, LP.2023: S61-S62
- **Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)**
van de Donk, N., Moreau, P., Garfall, A., Bhutani, M., Oriol, A., Nooka, A., Martin, T., Rosinol, L., Mateos, M., Bahlis, N., Popat, R., Besemer, B., Martinez Lopez, et al
CIG MEDIA GROUP, LP.2023: S477-S478
- **Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: real-world experience from the US myeloma CAR T consortium**
Afrough, A., Hashmi, H., Hansen, D., Sidana, S., Ahn, C., Dima, D., Freeman, C., Puglianini, O., Kocoglu, M., Atrash, S., Voorhees, P., Shune, L., Simmons, et al
CIG MEDIA GROUP, LP.2023: S33
- **Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.** *Blood cancer journal*
Ferreri, C. J., Hildebrandt, M. A., Hashmi, H., Shune, L. O., McGuirk, J. P., Sborov, D. W., Wagner, C. B., Kocoglu, M. H., Rapoport, A., Atrash, S., Voorhees, P. M., Khouri, J., Dima, et al
2023; 13 (1): 117
- **First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (Pvd or DPd) in lenalidomide-refractory multiple myeloma.**
Yong, K., Harrison, S. J., Mateos, M., Moreau, P., van de Donk, N. J., Sidana, S., Popat, R., Lendvai, N., Lonardi, C., Slaughter, A., Schecter, J., Li, K., Zudaire, et al
LIPPINCOTT WILLIAMS & WILKINS.2023: LBA106
- **First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (Pvd or DPd) in lenalidomide-refractory multiple myeloma.**
Dhakal, B., Yong, K., Harrison, S. J., Mateos, M., Moreau, P., van de Donk, N. J., Sidana, S., Popat, R., Lendvai, N., Lonardi, C., Slaughter, A., Schecter, J., Li, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.** *The New England journal of medicine*
San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M. V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., Leleu, X., Avivi, I., Cavo, et al
2023
- **Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM).**
Hansen, D. K., Patel, K. K., Peres, L. C., Kocoglu, M. H., Shune, L., Simmons, G., Ferreri, C. J., Atrash, S., Parrondo, R., Chhabra, S., Costello, P., Midha, S., Alsina, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Embracing Myeloma Chimeric Antigen Receptor-T: From Scientific Design to Clinical Impact.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*
Hosoya, H., Rodriguez-Otero, P., Sidana, S., Borrello, I. M.
2023; 43: e389860
- **Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).**
van de Donk, N. J., Moreau, P., Garfall, A. L., Bhutani, M., Oriol, A., Nooka, A. K., Martin, T. G., Rosinol, L., Mateos, M., Bahlis, N. J., Popat, R., Besemer, B., Martinez-Lopez, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world experience from the US myeloma CAR T consortium.**

Afrough, A., Hashmi, H., Hansen, D. K., Sidana, S., Ahn, C., Dima, D., Freeman, C. L., Puglianini, O., Kocoglu, M. H., Atrash, S., Voorhees, P. M., Shune, L., Simmons, et al
LIPPINCOTT WILLIAMS & WILKINS.2023

- **Reply to R. Chakraborty et al.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Hansen, D. K., Sidana, S., Peres, L. C., Patel, K. K.
2023: JCO2300568
- **Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma.** *Future oncology (London, England)*
Moreau, P., van de Donk, N. W., Nahi, H., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Karlin, L., Benboubker, L., Mateos, M., Popat, R., Martinez-Lopez, J., Sidana, et al
2023
- **Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.** *Cancer*
Bumma, N., Dhakal, B., Fraser, R., Estrada-Merly, N., Anderson, K., Freytes, C. O., Hildebrandt, G. C., Holmberg, L., Krem, M. M., Lee, C., Lekakis, L., Lazarus, H. M., Mian, et al
2023
- **Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.** *Nature medicine*
Mailankody, S., Matous, J. V., Chhabra, S., Liedtke, M., Sidana, S., Oluwole, O. O., Malik, S., Nath, R., Anwer, F., Cruz, J. C., Htut, M., Karski, E. E., Lovelace, et al
2023
- **Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.** *Nature medicine*
Mailankody, S., Matous, J. V., Chhabra, S., Liedtke, M., Sidana, S., Oluwole, O. O., Malik, S., Nath, R., Anwer, F., Cruz, J. C., Htut, M., Karski, E. E., Lovelace, et al
2023
- **Ethical challenges with multiple myeloma BCMA CAR-T slot allocation: a multi-institution experience.** *Transplantation and cellular therapy*
Kourelis, T., Bansal, R., Berdeja, J., Siegel, D., Patel, K., Mailankody, S., Htut, M., Shah, N., Wong, S. W., Sidana, S., Cowan, A. J., Alsina, M., Cohen, et al
2023
- **Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Hansen, D. K., Sidana, S., Peres, L. C., Colin Leitzinger, C., Shune, L., Shrewsbury, A., Gonzalez, R., Sborov, D. W., Wagner, C., Dima, D., Hashmi, H., Kocoglu, M. H., Atrash, et al
2023: JCO2201365
- **Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis.** *ClinicoEconomics and outcomes research : CEOR*
Gertz, M., Abonour, R., Gibbs, S. N., Finkel, M., Landau, H., Lentzsch, S., Lin, G., Mahindra, A., Quock, T., Rosenbaum, C., Rosenzweig, M., Sidana, S., Tuchman, et al
2023; 15: 673-680
- **Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias.** *Seminars in oncology*
Testa, S., Kumar, J., Goodell, A. J., Zehnder, J. L., Alexander, K. M., Sidana, S., Arai, S., Witteles, R. M., Liedtke, M.
2022
- **Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA**
Hosoya, H., Carleton, M., Tanaka, K. L., Sworder, B., Hovanky, V., Duran, G. E., Zhang, T. Y., Khodadoust, M. S., Miklos, D. B., Arai, S., Iberri, D., Liedtke, M., Sidana, et al
AMER SOC HEMATOLOGY.2022: 1546-1548
- **Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects**
Hamilton, M. P., Liu-Fei, F. C., Alig, S. K., Tamaresis, J., Esfahani, M., Good, Z., Sworder, B., Schroers-Martin, J., Liu, C., Severinsen, F., Hanson, P. J., Lu, Y., Lowsky, et al

AMER SOC HEMATOLOGY.2022: 7545-7547

● **The Development of Carhlh after Axicabtagene Ciloleucl Is Associated with Poor Outcomes**

Philip, S., Srinagesh, H. K., Hamilton, M. P., Gentile, C., Mina, A., Arai, S., Johnston, L. J., Lowsky, R., Meyer, E. H., Negrin, R. S., Rezvani, A. R., Shiraz, P., Shizuru, et al

AMER SOC HEMATOLOGY.2022: 12775-12777

● **Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref NonHodgkin Lymphoma**

Bharadwaj, S., Hamilton, M. P., Sahaf, B., Tamaresis, J., Patil, S., Hanson, P. J., Latchford, T., Arai, S., Johnston, L. J., Lowsky, R., Negrin, R. S., Rezvani, A. R., Shizuru, et al

AMER SOC HEMATOLOGY.2022: 10371-10373

● **Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucl: The US Myeloma CAR T Consortium Real World Experience**

Khouri, J., Li, H., Hansen, D. K., Sidana, S., Shune, L. O., DeJarnette, S., Anwer, F., Sborov, D. W., Wagner, C. B., Kocoglu, M., Atrash, S., Voorhees, P. M., Valent, et al

AMER SOC HEMATOLOGY.2022: 10427-10429

● **Idecabtagene Vicleucl Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience**

Sidana, S., Peres, L. C., Hashmi, H., Hosoya, H., Ferreri, C. J., Atrash, S., Khouri, J., Voorhees, P. M., Dima, D., Simmons, G., Kalariya, N., Hovanky, V., Bharadwaj, et al

AMER SOC HEMATOLOGY.2022: 10377-10379

● **Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucl (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): US Myeloma CAR T Consortium Real World Experience**

Hashmi, H., Hansen, D. K., Peres, L. C., Puglianini, O., Freeman, C. L., De Avila, G., Sidana, S., Shune, L. O., Sborov, D. W., Davis, J., Wagner, C. B., Kocoglu, M., Atrash, et al

AMER SOC HEMATOLOGY.2022: 4642-4645

● **Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy**

Peres, L. C., Oswald, L. B., Dillard, C., De Avila, G., Nishihori, T., Blue, B. J., Freeman, C. L., Locke, F. L., Alsina, M., Puglianini, O., Shune, L. O., Sborov, D. W., Wagner, et al

AMER SOC HEMATOLOGY.2022

● **Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma**

Mailankody, S., Matous, J., Liedtke, M., Sidana, S., Oluwole, O. O., Mohan, M., Cruz, J. C., Nath, R., Anwer, F., Rossi, A., Htut, M., Malik, S. A., Ghatta, et al

AMER SOC HEMATOLOGY.2022: 4620-4622

● **Early cytopenias and infections after standard of care icleucl#in relapsed or refractory multiple myeloma. *Blood advances***

Logue, J. M., Peres, L. C., Hashmi, H., Colin-Leitzinger, C., Shrewsbury, A. M., Hosoya, H., Gonzalez, R., Copponex, C., Kottra, K. H., Hovanky, V., Sahaf, B., Patil, S., Lazaryan, et al

2022

● **Idecabtagene vicleucl chimeric antigen receptor T-cell therapy for relapsed and refractory multiple myeloma: real-world experience**

Hansen, D., Sidana, S., Peres, L., Leitzinger, C., Shune, L., Shrewsbury, A., Gonzalez, R., Sborov, D., Wagner, C., Hashmi, H., Kocoglu, M., Atrash, S., Simmons, et al

CIG MEDIA GROUP, LP.2022: S2-S3

● **Teclistamab in Relapsed or Refractory Multiple Myeloma. *The New England journal of medicine***

Moreau, P., Garfall, A. L., van de Donk, N. W., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., Karlin, L., Benboubker, L., Mateos, et al

2022

● **Ethical challenges with CAR T slot allocation with icleucl manufacturing access.**

Kourelis, T., Bansal, R., Patel, K. K., Berdeja, J. G., Raju, N. S., Alsina, M., Cohen, A. D., Siegel, D., Mailankody, S., Htut, M., Sidana, S., Holstein, S. A., Cowan, et al

LIPPINCOTT WILLIAMS & WILKINS.2022

● **Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1.**

Nooka, A. K., Moreau, P., Usmani, S., Garfall, A. L., Van De Donk, N. J., San-Miguel, J. F., Oriol Rocafiguera, A., Chari, A., Karlin, L., Mateos, M., Popat, R., Martinez, J., Sidana, et al
LIPPINCOTT WILLIAMS & WILKINS.2022

- **Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience.**
Hansen, D. K., Sidana, S., Peres, L., Shune, L., Sborov, D. W., Hashmi, H., Kocoglu, M. H., Atrash, S., Simmons, G., Kalariya, N., Ferreri, C. J., Afrough, A., Kansagra, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care.** *JCO oncology practice*
Sidana, S., Allmer, C., Larson, M. C., Dueck, A., Yost, K., Warsame, R., Thanarajasingam, G., Cerhan, J. R., Paludo, J., Rajkumar, S. V., Habermann, T. M., Nowakowski, G. S., Lin, et al
2022: OP2100789
- **Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era.** *Transplantation and cellular therapy*
Liang, E. C., Craig, J., Torelli, S., Cunanan, K., Iglesias, M., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., Negrin, R., Rezvani, et al
2022
- **Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy vs Autologous and Allogeneic Stem Cell Transplant.** *Transplantation and cellular therapy*
Sidana, S., Dueck, A. C., Thanarajasingam, G., Griffin, J. M., Thompson, C., Durani, U., Burtis, M., Warsame, R., Paludo, J., Gertz, M. A., Dispenzieri, A., Ansell, S. M., Rajkumar, et al
2022
- **Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies.** *The Lancet. Haematology*
Thanarajasingam, G., Minasian, L. M., Bhatnagar, V., Cavalli, F., De Claro, R. A., Dueck, A. C., El-Galaly, T. C., Everest, N., Geissler, J., Gisselbrecht, C., Gormley, N., Gribben, J., Horowitz, et al
2022; 9 (5): e374-e384
- **Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies** *LANCET HAEMATOLOGY*
Thanarajasingam, G., Minasian, L. M., Bhatnagar, V., Cavalli, F., De Claro, R., Dueck, A. C., El-Galaly, T. C., Everest, N., Geissler, J., Gisselbrecht, C., Gormley, N., Gribben, J., Horowitz, et al
2022; 9 (5): E374-E384
- **Updated Results From the Phase 1/2 MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma**
Popat, R., Usmani, S. Z., Garfall, A., van de Donk, N., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A., Martin, T., Rosinol, L., Chari, A., Karlin, L., Benboubker, et al
WILEY.2022: 35-36
- **Real-world Experience of Cryopreserved Allogeneic Hematopoietic Grafts in the COVID-19 Pandemic: A Single Center Report.** *Transplantation and cellular therapy*
Bankova, A. K., Caveney, J., Yao, B., Ramos, T. L., Bogeholz, J., Heydari, K., Diaz, N., Jackson, M. L., Lowsky, R., Brown, J. W., Johnston, L., Rezvani, A. R., Frank, et al
1800
- **Differential Diagnosis of Waldenström's Macroglobulinemia and Early Management: Perspectives from Clinical Practice** *BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY*
Cingam, S., Sidana, S.
2022; 12: 107-117
- **Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma.** *Blood advances*
Kansagra, A., Dispenzieri, A., Fraser, R., Estrada-Merly, N., Sidana, S., Nishihori, T., Hansen, D. K., Anderson, L. D., Banerjee, R., Bumma, N., Dhakal, B., Khouri, J., Landau, et al
2022

- **Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma**
Moreau, P., Usmani, S. Z., Garfall, A. L., van de Donk, N. J., Nahi, H., San-Miguel, J., Oriol, A., Nooka, A. K., Martin, T., Rosino, L., Chari, A., Karlin, L., Benboubker, et al
AMER SOC HEMATOLOGY.2021
- **Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma**
Mailankody, S., Liedtke, M., Sidana, S., Matous, J. V., Chhabra, S., Oluwole, O. O., Malik, S. A., Kumar, S., Nath, R., Anwer, F., Cruz, J., Jagannath, S., Htut, et al
AMER SOC HEMATOLOGY.2021
- **Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell (CAR-T) Therapy: A Mixed Methods Longitudinal Study**
Cusatis, R., Tan, I., Piehowski, C., Akinola, I., Crawford, E., Craig, J., Thiengmany, A., Frank, M. J., Miklos, D. B., Shah, N. N., D'Souza, A., Knight, J. M., Muffy, et al
AMER SOC HEMATOLOGY.2021
- **Do PROs Tell the Whole Story? Differential Outcomes Based on Patient Reported Outcomes (PROs) Versus Performance-Based Metrics (PBM) on Cognition for Patients Receiving Chimeric Antigen Receptor (CAR)-T Cell Therapy**
Tan, I., Cusatis, R., Crawford, E., Thiengmany, A., Piehowski, C., Akinola, I., Craig, J., Lahijani, S., Frank, M. J., Shah, N. N., D'Souza, A., Miklos, D. B., Muffy, et al
AMER SOC HEMATOLOGY.2021
- **Mgta-145+Plerixafor Provides GCSF-Free Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study**
Sidana, S., Bankova, A. K., Hosoya, H., Kumar, S., Tamaresis, J., Le, A., Muffy, L., Johnston, L. J., Arai, S., Lowsky, R., Meyer, E. H., Rezvani, A. R., Weng, et al
AMER SOC HEMATOLOGY.2021
- **CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy**
Frank, M. J., Baird, J. H., Patel, S., Craig, J., Spiegel, J. Y., Ehlinger, Z., Chinnasamy, H., Younes, S. F., Oak, J. S., Natkunam, Y., Reynolds, W. D., Iglesias, M., Crawford, et al
AMER SOC HEMATOLOGY.2021
- **Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy** *BLOOD ADVANCES*
Johnsrud, A., Craig, J., Baird, J., Spiegel, J., Muffy, L., Zehnder, J., Tamaresis, J., Negrin, R., Johnston, L., Arai, S., Shizuru, J., Lowsky, R., Meyer, et al
2021; 5 (21): 4465-4475
- **Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.** *Blood advances*
Muffy, L., Sundaram, V., Chen, C., Yurkiewicz, I., Kuo, E., Burnash, S., Spiegel, J. Y., Arai, S., Frank, M. J., Johnston, L. J., Lowsky, R., Meyer, E. H., Negrin, et al
2021; 5 (16): 3147-3151
- **CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.** *Nature medicine*
Spiegel, J. Y., Patel, S., Muffy, L., Hossain, N. M., Oak, J., Baird, J. H., Frank, M. J., Shiraz, P., Sahaf, B., Craig, J., Iglesias, M., Younes, S., Natkunam, et al
2021
- **Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma.** *Bone marrow transplantation*
Lemieux, C., Muffy, L. S., Iberri, D. J., Craig, J. K., Johnston, L. J., Lowsky, R., Shiraz, P., Rezvani, A. R., Frank, M. J., Weng, W., Meyer, E., Shizuru, J. A., Arai, et al
2021
- **Inferior Clinical Outcomes in Recipients of Cryopreserved Grafts Following Reduced Intensity Allogeneic Hematopoietic Cell Transplantation: A Single Center Report**
Bankova, A., Caveney, J., Ramos, T., Bogeholz, J., Heydari, K., Diaz, N., Jackson, M., Lowsky, R., Brown, J., Johnston, L., Rezvani, A., Frank, M., Muffy, et al

SPRINGER NATURE.2021: 181

- **Phase 2 study of MGTA-145+plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma.**
Sidana, S., Bankova, A., Hosoya, H., Muffly, L. S., Kumar, S., Johnston, L. J., Lowsky, R., Meyer, E., Rezvani, A., Weng, W., Arai, S., Frank, M., Shiraz, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis.** *Blood advances*
Sidana, S., Dasari, S., Kourelis, T. V., Dispenzieri, A., Murray, D. L., King, R. L., McPhail, E. D., Ramirez-Alvarado, M., Kumar, S. K., Gertz, M. A.
2021; 5 (8): 2101–5
- **Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era.** *Transplantation and cellular therapy*
Johnsrud, A., Ladha, A., Muffly, L., Shiraz, P., Goldstein, G., Osgood, V., Shizuru, J. A., Johnston, L., Arai, S., Weng, W., Lowsky, R., Rezvani, A. R., Meyer, et al
2021
- **Antibody-Based Treatment Approaches in Multiple Myeloma.** *Current hematologic malignancy reports*
Hosoya, H., Sidana, S.
2021
- **Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group** *LANCET ONCOLOGY*
Moreau, P., Kumar, S. K., Miguel, J., Davies, F., Zamagni, E., Bahlis, N., Ludwig, H., Mikhael, J., Terpos, E., Schjesvold, F., Martin, T., Yong, K., Durie, et al
2021; 22 (3): E105–E118
- **Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.** *Transplantation and cellular therapy*
Liang, E. C., Muffly, L. S., Shiraz, P., Shizuru, J. A., Johnston, L., Arai, S., Frank, M. J., Weng, W., Lowsky, R., Rezvani, A., Meyer, E. H., Negrin, R., Miklos, et al
2021
- **Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma** *BLOOD ADVANCES*
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., Claire, G. K., Frank, M. J., Muffly, L., Shiraz, P., Meyer, E., Arai, S., Brown, et al
2021; 5 (1): 143–55
- **Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.** *The Lancet Oncology*
Moreau, P. n., Kumar, S. K., San Miguel, J. n., Davies, F. n., Zamagni, E. n., Bahlis, N. n., Ludwig, H. n., Mikhael, J. n., Terpos, E. n., Schjesvold, F. n., Martin, T. n., Yong, K. n., Durie, et al
2021; 22 (3): e105–e118
- **Title: Impact of Induction Therapy with VRD vs. VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation.** *Transplantation and cellular therapy*
Sidana, S., Kumar, S., Fraser, R., Estrada-Merly, N., Giral, S., Agrawal, V., Anderson, L. D., Aljurf, M., Banerjee, R., Bashey, A., Battiwalla, M., Beitinjaneh, A., Chakraborty, et al
2021
- **Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy.** *Blood advances*
Johnsrud, A. J., Craig, J., Baird, J. H., Spiegel, J. Y., Muffly, L., Zehnder, J. L., Tamaresis, J. S., Negrin, R. S., Johnston, L., Arai, S., Shizuru, J. A., Lowsky, R., Meyer, et al
2021
- **Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort.** *American journal of hematology*
Drosou, M. E., Vaughan, L. E., Muchtar, E. n., Buadi, F. K., Dingli, D. n., Dispenzieri, A. n., Fonder, A. L., Gertz, M. A., Go, R. S., Gonsalves, W. I., Hayman, S. R., Hobbs, M. A., Hwa, et al

2021

- **Outcomes with different administration schedules of Bortezomib in Bortezomib, Lenalidomide and dexamethasone (VRd) as first-line therapy in Multiple Myeloma.** *American journal of hematology*
Cook, J., Johnson, I., Higgins, A., Sidana, S., Warsame, R., Gonsalves, W., Gertz, M. A., Buadi, F., Lacy, M., Kapoor, P., Dispenzieri, A., Kourelis, T., Dingli, et al
2020
- **Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
Lemieux, C., Johnston, L. J., Lowsky, R., Muffly, L. S., Craig, J. K., Shiraz, P., Rezvani, A., Frank, M. J., Weng, W., Meyer, E., Shizuru, J., Arai, S., Negrin, et al
2020
- **International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.** *Leukemia*
Costa, L. J., Derman, B. A., Bal, S., Sidana, S., Chhabra, S., Silbermann, R., Ye, J. C., Cook, G., Cornell, R. F., Holstein, S. A., Shi, Q., Omel, J., Callander, et al
2020
- **Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis.** *Bone marrow transplantation*
Abdallah, N., Sidana, S., Dispenzieri, A., Lacy, M., Buadi, F., Hayman, S., Kapoor, P., Leung, N., Dingli, D., Hwa, Y. L., Lust, J., Russell, S., Gonsalves, et al
2020
- **Quality of life (QOL), financial burden, and perception of care in patients enrolled on clinical trials (CTs).**
Sidana, S., Allmer, C., Larson, M. C., Dueck, A. C., Yost, K. J., Warsame, R. M., Thanarajasingam, G., Cerhan, J., Paludo, J., Rajkumar, S., Habermann, T., Nowakowski, G. S., Lin, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM).**
Tam, E., Iberri, D., Liedtke, M., Muffly, L. S., Shiraz, P., Frank, M., Lowsky, R., Rezvani, A., Negrin, R., Meyer, E., Arai, S., Johnston, L. J., Shizuru, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Glycosylation of Immunoglobulin Light Chains is Highly Prevalent in Cold Agglutinin Disease.** *American journal of hematology*
Sidana, S., Murray, D. L., Dasari, S., Go, R. S., Muchtar, E., Willrich, M. A., Snyder, M., Kohlhagen, M., Lust, J. A., Kourelis, T. V., Kumar, S. K., Dispenzieri, A., Gertz, et al
2020
- **A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis.** *Blood cancer journal*
Sidana, S., Milani, P., Binder, M., Basset, M., Tandon, N., Foli, A., Dispenzieri, A., Gertz, M. A., Hayman, S. R., Buadi, F. K., Lacy, M. Q., Kapoor, P., Leung, et al
2020; 10 (4): 41
- **Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era**
Muffly, L., Arai, S., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., Negrin, R. S., Rezvani, A., Shiraz, P., Shizuru, J. A., Sidana, S., Weng, W., Cunanan, et al
ELSEVIER SCIENCE INC.2020: S106
- **Impact of Minimal Residual Negativity using Next Generation Flow Cytometry on Outcomes in Light Chain Amyloidosis.** *American journal of hematology*
Sidana, S., Muchtar, E., Sidiqi, M. H., Jevremovic, D., Dispenzieri, A., Gonsalves, W., Buadi, F., Lacy, M. Q., Hayman, S. R., Kourelis, T., Kapoor, P., Go, R. S., Warsame, et al
2020
- **Organ responses with daratumumab therapy in previously treated AL amyloidosis.** *Blood advances*
Chung, A. n., Kaufman, G. P., Sidana, S. n., Eckhart, E. n., Schrier, S. L., Lafayette, R. A., Arai, S. n., Witteles, R. M., Liedtke, M. n.
2020; 4 (3): 458–66
- **CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.** *Blood*

- Baird, J. H., Frank, M. J., Craig, J. n., Patel, S. n., Spiegel, J. Y., Sahaf, B. n., Oak, J. S., Younes, S. n., Ozawa, M. n., Yang, E. n., Natkunam, Y. n., Tamaresis, J. S., Ehlinger, et al
2020
- **Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.** *Bone marrow transplantation*
Lemieux, C. n., Muffy, L. S., Rezvani, A. n., Lowsky, R. n., Iberri, D. J., Craig, J. K., Frank, M. J., Johnston, L. J., Liedtke, M. n., Negrin, R. n., Weng, W. K., Meyer, E. n., Shizuru, et al
2020
 - **Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?**
Sidana, S., Manasanch, E.
AMER SOC HEMATOLOGY.2019: 142–47
 - **CAR T-cell therapy: is it prime time in myeloma?**
Sidana, S., Shah, N.
AMER SOC HEMATOLOGY.2019: 260–65
 - **Revisiting complete response in light chain amyloidosis.** *Leukemia*
Sidana, S., Dispenzieri, A., Murray, D. L., Go, R. S., Buadi, F. K., Lacy, M. Q., Gonsalves, W. I., Dingli, D., Warsame, R., Kourelis, T., Muchtar, E., Hayman, S. R., Kapoor, et al
2019
 - **Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis.** *Leukemia*
Muchtar, E., Gertz, M. A., Kourelis, T. V., Sidana, S., Go, R. S., Lacy, M. Q., Buadi, F. K., Dingli, D., Hayman, S. R., Kapoor, P., Leung, N., Fonder, A., Hobbs, et al
2019
 - **Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL Amyloidosis**
Chung, A., Kaufman, G. P., Sidana, S., Eckhert, E., Schrier, S., Arai, S., Lafayette, R., Witteles, R., Liedtke, M.
AMER SOC HEMATOLOGY.2019
 - **Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life**
Sidana, S., Thanarajasingam, G., Griffin, J., Thompson, C. A., Burtis, M., Warsame, R., Paludo, J., Cheville, A., Gertz, M. A., Dispenzieri, A., Villasboas, J., Ansell, S. M., Rajkumar, et al
AMER SOC HEMATOLOGY.2019
 - **Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease**
Sidana, S., Murray, D. L., Dasari, S., Go, R. S., Willrich, M., Snyder, M., Kohlhagen, M., Lust, J. A., Muchtar, E., Kourelis, T., Kumar, S. K., Dispenzieri, A., Gertz, et al
AMER SOC HEMATOLOGY.2019
 - **Immunoglobulin Variable Gene Region (IGVL) Usage Correlates with Distinct Clinical Presentation in IgM Versus Non-IgM Light Chain Amyloidosis**
Sidana, S., Dasari, S., Kourelis, T., Dispenzieri, A., Murray, D. L., King, R. L., McPhail, E. D., Ramirez-Alvarado, M., Kumar, S. K., Gertz, M. A.
AMER SOC HEMATOLOGY.2019
 - **Favorable Long-Term Outcomes after Daratumumab Discontinuation in AL Amyloidosis Patients Achieving Deep Responses**
Chung, A., Kaufman, G. P., Sidana, S., Iberri, D., Eckhert, E., Schrier, S., Lafayette, R., Arai, S., Witteles, R., Liedtke, M.
AMER SOC HEMATOLOGY.2019
 - **Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis** *AMERICAN JOURNAL OF HEMATOLOGY*
Al Saleh, A. S., Sidiqi, M., Sidana, S., Muchtar, E., Dispenzieri, A., Dingli, D., Lacy, M. Q., Warsame, R. M., Gonsalves, W. I., Kourelis, T. V., Hogan, W. J., Hayman, S. R., Wolf, et al
2019: 1066–71
 - **Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis** *AMERICAN JOURNAL OF HEMATOLOGY*
Sidana, S., Sidiqi, M., Dispenzieri, A., Buadi, F. K., Lacy, M. Q., Muchtar, E., Dingli, D., Haynman, S. R., Gonsalves, W., Kapoor, P., Leung, N., Warsame, R., Kourelis, et al

2019

- **Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis** *BRITISH JOURNAL OF HAEMATOLOGY*
Sidana, S., Tandon, N., Gertz, M. A., Dispenzieri, A., Ramirez-Alvarado, M., Murray, D. L., Kourelis, T. V., Buadi, F. K., Kapoor, P., Gonsalves, W., Warsame, R., Lacy, M. Q., Kyle, et al
2019; 185 (4): 701–7
- **Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
Chakraborty, R., Sidana, S., Shah, G. L., Scordo, M., Hamilton, B. K., Majhail, N. S.
2019; 25 (5): e155–e162
- **Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma** *AMERICAN JOURNAL OF HEMATOLOGY*
Sidana, S., Jevremovic, D., Ketterling, R. P., Tandon, N., Greipp, P. T., Baughn, L. B., Dispenzieri, A., Gertz, M. A., Rajkumar, S., Kumar, S. K.
2019; 94 (5): E117–E120
- **Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method** *AMERICAN JOURNAL OF HEMATOLOGY*
Sidana, S., Jevremovic, D., Ketterling, R. P., Tandon, N., Dispenzieri, A., Gertz, M. A., Greipp, P. T., Baughn, L. B., Buadi, F. K., Lacy, M. Q., Morice, W., Hanson, C., Timm, et al
2019; 94 (4): 424–30
- **Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma** *BLOOD ADVANCES*
Tandon, N., Sidana, S., Rajkumar, S., Gertz, M. A., Buadi, F. K., Lacy, M. Q., Kapoor, P., Gonsalves, W., Dispenzieri, A., Kourelis, T., Warsame, R., Dingli, D., Fonder, et al
2019; 3 (5): 744–50
- **Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis** *MAYO CLINIC PROCEEDINGS*
Sidana, S., Tandon, N., Brady, P. A., Grogan, M., Gertz, M. A., Dispenzieri, A., Lin, G., Dingli, D., Buadi, F. K., Lacy, M. Q., Kapoor, P., Gonsalves, W., Muchtar, et al
2019; 94 (3): 455–64
- **Primary systemic amyloidosis in patients with Waldenstrom macroglobulinemia** *LEUKEMIA*
Zanwar, S., Abeykoon, J. P., Ansell, S. M., Gertz, M. A., Dispenzieri, A., Muchtar, E., Sidana, S., Tandon, N., Rajkumar, S., Dingli, D., Go, R., Lacy, M. Q., Kourelis, et al
2019; 33 (3): 790–94
- **Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse** *LEUKEMIA*
Sidana, S., Tandon, N., Dispenzieri, A., Gertz, M. A., Buadi, F. K., Lacy, M. Q., Dingli, D., Fonder, A. L., Hayman, S. R., Hobbs, M. A., Gonsalves, W. I., Warsame, R. M., Kourelis, et al
2019; 33 (3): 730–38
- **A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses** *LEUKEMIA & LYMPHOMA*
McCarter, S. J., Vijayvargiya, P., Sidana, S., Nault, A. M., Lane, C. E., Lehman, J. S., Wilson, J. W., Parikh, S. A., Nowakowski, G. S., Al-Kali, A.
2019; 60 (2): 559–61
- **IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features.** *Leukemia*
Sidana, S. n., Larson, D. P., Greipp, P. T., He, R. n., McPhail, E. D., Dispenzieri, A. n., Murray, D. L., Dasari, S. n., Ansell, S. M., Muchtar, E. n., Gonsalves, W. I., Kourelis, T. V., Ramirez-Alvarado, et al
2019
- **Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?** *Hematology. American Society of Hematology. Education Program*
Sidana, S. n., Manasanch, E. n.
2019; 2019 (1): 142–47
- **CAR T-cell therapy: is it prime time in myeloma?** *Hematology. American Society of Hematology. Education Program*
Sidana, S. n., Shah, N. n.
2019; 2019 (1): 260–65

- **CAR T-cell therapy: is it prime time in myeloma?** *Blood advances*
Sidana, S. n., Shah, N. n.
2019; 3 (21): 3473–80
- **Should we measure clonal circulating plasma cells in light chain amyloidosis?** *Oncotarget*
Sidana, S., Kumar, S. K., Gonsalves, W. I.
2018; 9 (86): 35607–8
- **59-Year-Old Man With Fatigue, Weight Loss, and Hepatomegaly** *MAYO CLINIC PROCEEDINGS*
Orme, J. J., Sidana, S., Gonsalves, W. I.
2018; 93 (10): 1525–29
- **Reply to A. Piccardo et al, E. Hindie et al, MC Kreissl et al, M. Doss, J. Buscombe, R. Fisher, M. Sollini et al, M. Lichtenstein, and M. Tulchinsky et al** *JOURNAL OF CLINICAL ONCOLOGY*
Molenaar, R. J., Sidana, S., Radivoyevitch, T., Gerds, A. T., Carraway, H. E., Kalaycio, M., Nazha, A., Adelstein, D. J., Nasr, C., Maciejewski, J. P., Majhail, N. S., Sekeres, M. A., Mukherjee, et al
2018; 36 (18): 1889–+
- **Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer** *JOURNAL OF CLINICAL ONCOLOGY*
Molenaar, R. J., Sidana, S., Radivoyevitch, T., Advani, A. S., Gerds, A. T., Carraway, H. E., Angelini, D., Kalaycio, M., Nazha, A., Adelstein, D. J., Nasr, C., Maciejewski, J. P., Majhail, et al
2018; 36 (18): 1831–+
- **Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis** *LEUKEMIA*
Sidana, S., Tandon, N., Dispenzieri, A., Gertz, M. A., Dingli, D., Jevremovic, D., Morice, W. G., Kapoor, P., Kourelis, T. V., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Leung, et al
2018; 32 (6): 1421–26
- **The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response** *LEUKEMIA*
Sidana, S., Tandon, N., Dispenzieri, A., Gertz, M. A., Rajkumar, S., Kumar, S. K.
2018; 32 (5): 1243–46
- **Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis** *BONE MARROW TRANSPLANTATION*
Sidana, S., Tandon, N., Gertz, M. A., Dispenzieri, A., Buadi, F. K., Lacy, M. Q., Dingli, D., Fonder, A. L., Hayman, S. R., Hobbs, M. A., Gonsalves, W. I., Hwa, Y., Kapoor, et al
2018; 53 (3): 326–33
- **Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.** *Leukemia*
Sidana, S. n., Tandon, N. n., Dispenzieri, A. n., Gertz, M. A., Buadi, F. K., Lacy, M. Q., Dingli, D. n., Fonder, A. L., Hayman, S. R., Hobbs, M. A., Gonsalves, W. I., Hwa, Y. L., Kapoor, et al
2018; 32 (3): 729–35
- **Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL)** *AMERICAN JOURNAL OF HEMATOLOGY*
Tandon, N., Sidana, S., Dispenzieri, A., Gertz, M. A., Lacy, M. Q., Dingli, D., Buadi, F. K., Fonder, A. L., Hayman, S. R., Hwa, Y., Hobbs, M. A., Kapoor, P., Gonsalves, et al
2018; 93 (1): 17–22
- **Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine.** *Leukemia*
Molenaar, R. J., Pleyer, C. n., Radivoyevitch, T. n., Sidana, S. n., Godley, A. n., Advani, A. S., Gerds, A. T., Carraway, H. E., Kalaycio, M. n., Nazha, A. n., Adelstein, D. J., Nasr, C. n., Angelini, et al
2018; 32 (4): 952–59
- **Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia** *AMERICAN JOURNAL OF HEMATOLOGY*
Sidana, S., Rajkumar, S., Dispenzieri, A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Hayman, S. R., Dingli, D., Kapoor, P., Gonsalves, W. I., Go, R. S., Hwa, Y., Leung, et al
2017; 92 (7): 668–73
- **Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis** *AMERICAN JOURNAL OF HEMATOLOGY*

- Tandon, N., Sidana, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Buadi, F. K., Dingli, D., Fonder, A. L., Hobbs, M. A., Hayman, S. R., Gonsalves, W. I., Hwa, Y., Kapoor, et al
2017; 92 (6): 549–54
- **Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis.** *PloS one*
Sidana, S., Narkhede, M., Elson, P., Hastings, D., Faiman, B., Valent, J., Samaras, C., Hamilton, K., Liu, H. K., Smith, M. R., Reu, F. J.
2017; 12 (3): e0172996
 - **Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival.** *Bone marrow transplantation*
Tandon, N. n., Muchtar, E. n., Sidana, S. n., Dispenzieri, A. n., Lacy, M. Q., Dingli, D. n., Buadi, F. K., Hayman, S. R., Chakraborty, R. n., Hogan, W. J., Gonsalves, W. n., Warsame, R. n., Kourelis, et al
2017; 52 (8): 1126–32
 - **Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis** *AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS*
Tandon, N., Sidana, S., Rajkumar, S., Dispenzieri, A., Gertz, M. A., Lacy, M. Q., Kyle, R. A., Buadi, F. K., Dingli, D., Hayman, S. R., Fonder, A. L., Hobbs, M. A., Gonsalves, et al
2017; 24 (3): 183–88
 - **Got zinc? An exfoliative rash in a parenteral nutrition-dependent patient.** *Journal of general internal medicine*
Sidana, S., Madanat, Y., Pile, J.
2015; 30 (4): 529-30
 - **Symptomatic and incidental venous thromboembolic disease are both associated with mortality in patients with prostate cancer.** *PloS one*
Chaturvedi, S., Sidana, S., Elson, P., Khorana, A. A., McCrae, K. R.
2014; 9 (8): e94048
 - **Prevalence of depression in students of a medical college in New Delhi: A cross-sectional study** *AUSTRALASIAN MEDICAL JOURNAL*
Sidana, S., Kishore, J., Ghosh, V., Gulati, D., Jiloha, R. C., Anand, T.
2012; 5 (5): 247–50